•
Jun 30, 2022
Nuwellis Q2 2022 Earnings Report
Reported a 15% sequential increase in revenue and a decrease in operating expenses.
Key Takeaways
Nuwellis, Inc. reported a total revenue of $2.2 million for Q2 2022, representing a 15% increase compared to the previous quarter. The company's net loss was $4.3 million, and cash and cash equivalents totaled $15.3 million as of June 30, 2022.
Total revenue for Q2 2022 was $2.2 million, up 15% sequentially.
First patient enrolled in REVERSE-HF clinical trial.
Operating expenses decreased 14% compared to Q2 2021.
Gross margin was 48.0%, impacted by lower fixed overhead absorption and a non-cash inventory write-off.
Nuwellis
Nuwellis
Forward Guidance
Nuwellis anticipates continued growth and strategic advancements for the remainder of 2022 and into 2023, focusing on making the Aquadex System the standard of care.